| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4262431 | Transplantation Proceedings | 2005 | 4 Pages |
Abstract
The alternative 2-dose regimen of daclizumab was as safe and effective as the conventional 5-dose regimen compared to no antibody induction in SKPT patients, but no long-term benefits were noted.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
R.J. Stratta, R.R. Alloway, A. Lo, E.E. Hodge, Pancreas Investigators Vital Outcomes Trial (PIVOT) Study Group Pancreas Investigators Vital Outcomes Trial (PIVOT) Study Group,